Investlytic Investlytic
Log in Free Account
English
🕒 Last update: loading…09/11/2026

Stock Boston Scientific Corporation BSX

Boston Scientific Corporation — Investlytic score 2/5 on the five criteria.

-
-
40/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 2/5 criteria met. Data as of 01/11/2026.

  • ❌ Price trend failed
  • ✅ Growth passed
  • ❌ Debt failed
  • ✅ P/E passed
  • ❌ Correction failed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2018 → 2019: 27.96%

Price change 2019 → 2020: -20.50%

Price change 2020 → 2021: 18.16%

Price change 2021 → 2022: 8.92%

Price change 2022 → 2023: 24.94%

Price change 2023 → 2024: 54.51%

Price change 2024 → 2025: 6.75%

Price change 2025 → 2026: -55.97%

Price change 2026 (year to date): -55.68%

Financial growth

Revenue CAGR (8 years): 10.75%

Earnings CAGR (8 years): 8.12%

Growth status: positive trend (>1%/yr) in revenue and earnings.

Debt

Debt-to-equity ratio: 0.51

Debt/equity > 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: 13.54

P/E < 25.0 (maximum threshold).

Correction (6 months)

Current correction: 27.35% from the high over 6 months.

Excessive correction (> 20.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

Create a free account Log in
02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
Boston Scientific Corporation13.50.51+6.5 %🔒
Lonza Group AG40.40.50+6.1 %–
Becton, Dickinson and Company15.20.76+7.8 %–
Merck KGaA18.00.42+5.6 %–
Sandoz Group AG69.20.61+5.5 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

Create a free account Log in
04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

Create a free account Log in
05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

Create a free account Log in
06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

Create a free account Log in
+

Key reported figures

Revenue, net income and net margin reported by Boston Scientific Corporation over the latest fiscal years.

Revenue
20.1 bn USD
fiscal year 2025
Net income
2.9 bn USD
fiscal year 2025
Net margin
14.4 %
fiscal year 2025
Average annual growth
+15.2 %
Revenue growth over 5 years
Average annual growth
+10.4 %
Revenue growth over 10 years
Market cap
62.0 bn USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
20209.9 bn-82.0 m-0.8 %n/a
202111.9 bn1.0 bn8.8 %+19.9 %
202212.7 bn698 m5.5 %+6.7 %
202314.2 bn1.6 bn11.2 %+12.3 %
202416.7 bn1.9 bn11.1 %+17.6 %
202520.1 bn2.9 bn14.4 %+19.9 %

Amounts converted to USD. Source: published annual accounts, collected on 06/11/2026.

+

Accounts and financial health

Balance sheet and cash flow published by Boston Scientific Corporation over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
average accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
2.99
gray zone (1.81 to 2.99)
Piotroski Score
6 / 9
4 to 6: average accounts
DCF Value
91.28 USD
DCF above share price · share price 43.11 USD, gap +111.7 %
Net Debt / EBITDA
2.10 x
moderate debt
Fiscal year20212022202320242025
Cash and investments1.9 bn928 m865 m414 m2.0 bn
Total Debt9.5 bn9.3 bn9.5 bn11.1 bn12.4 bn
Net Debt7.5 bn8.4 bn8.6 bn10.7 bn10.4 bn
Equity16.6 bn17.6 bn19.3 bn21.8 bn24.2 bn
Total assets32.2 bn32.5 bn35.1 bn39.4 bn43.7 bn
Operating cash flow1.9 bn1.5 bn2.5 bn3.4 bn4.5 bn
Investments (capex)554 m612 m711 m790 m876 m
Free cash-flow1.3 bn914 m1.7 bn2.6 bn3.7 bn
Share buybacks0-136 m000
Dividends paid55.0 m55.0 m28.0 m00

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)18.04 x
Price / book value2.42 x
Return on Equity (ROE)13.9 %
Return on Invested Capital (ROIC)10.5 %
Net margin16.6 %
Debt / equity0.47 x
Current ratio1.36 x
Interest coverage11.80 x
Free cash-flow yield5.4 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 09/11/2026.

+

Valuation and competitors

Boston Scientific Corporation compared with its sector on the same exchange and with its main competitors.

Company P/E
13.8
48.5 % below the sector
Sector median P/E
26.8
healthcare, NYSE
Sector over 10 years
22.3
10-year median, range 18.4 to 44.9

Direct competitors

CompanyMarket cap (USD)P/ENet margin
Boston Scientific Corporation60.8 bn13.514.4 %
Medtronic plc MDT123 bn17.513.9 %
Edwards Lifesciences Corporation EW53.0 bn34.117.7 %
LivaNova PLC LIVN4.3 bn18.8-17.5 %
Penumbra, Inc. PEN12.6 bn83.312.7 %
Teleflex Incorporated TFX5.9 bn16.0-45.5 %
Merit Medical Systems, Inc. MMSI5.2 bn22.18.5 %
AtriCure, Inc. ATRC3.1 bn1,902.2-2.1 %
CONMED Corporation CNMD1.3 bn9.73.4 %
Sector median (NYSE)26.8

Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on . Competitors: comparable companies named by the data provider.

+

Analyst consensus and forecasts

What the financial analysts covering Boston Scientific Corporation publish: ratings, price targets and earnings forecasts.

Majority rating
buy
44 analysts
Average price target
54.65 USD
from 46.00 USD to 71.00 USD, 82 targets over 12 months
Gap with the share price
+30.2 %
price 41.98 USD on 30/10/2026

Breakdown of ratings

strong buy 1buy 33hold 10sell 0strong sell 0

Analysts' average target 54.65 USD, DCF value 91.28 USD, share price 41.98 USD.

Average target over the last 3 months: 51.44 USD (16 targets).

Analyst forecasts

Fiscal yearRevenueNet incomeExpected EPS (range)P/E on this EPSAnalysts
202621.0 bn4.8 bn3.18 (3.12 / 3.30)13.216
202721.0 bn4.6 bn3.17 (3.04 / 3.57)13.217
202822.2 bn4.9 bn3.40 (2.80 / 4.14)12.310

Amounts in USD, the reporting currency.

Track record against expectations: reported EPS above consensus 12 times over the last 12 releases.

Rating changes (12 months)

DateFirmBeforeAfter
30/10/2026BarclaysEqual WeightEqual Weight
30/10/2026TD CowenBuyHold
29/10/2026JefferiesBuyHold
29/10/2026Canaccord GenuityBuyBuy
29/10/2026BTIGBuyBuy

Source: ratings and forecasts published by analysts, collected on 07/11/2026. An analyst rating or target is not a guarantee.

+

Dividends and earnings

Boston Scientific Corporation: dividend history, last distributions, stock splits and earnings releases.

No known dividend for this company.

Earnings releases

DatePublished EPSExpected EPSSurprise
28/10/20260.730.73+0.4 %
29/07/20260.860.83+3.0 %
22/04/20260.800.79+1.5 %
04/02/20260.800.78+2.4 %
22/10/20250.750.71+5.0 %
23/07/20250.750.72+3.4 %

Stock splits

DateOperation
06/11/2003split: 2 shares for 1
01/12/1998split: 2 shares for 1

Factual data: ex-dividend history and earnings calendar, as of 05/11/2026. A past dividend does not guarantee the next one.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in Boston Scientific Corporation.

Free float
99.3 %
share of freely traded shares
Large funds tracked
35
hold the stock as of 2026Q2
Executives (insiders)
6 / 0
6 purchases, 0 sales in 130 days
US elected officials
35
16 purchases, 19 sales in 12 months

Indices: S&P 500 (since 24/02/1995).

Large funds tracked

FundSharesValue (USD)Weight in the fundChangeQuarter
Vanguard Group140 m13.3 bn0.2 %+1.0 %2025Q4
State Street140 m6.0 bn0.1 %+106.2 %2026Q2
BlackRock130 m5.5 bn0.1 %-1.6 %2026Q2
Primecap Management50.5 m2.2 bn1.3 %+55.3 %2026Q2
Fidelity45.7 m2.0 bn0.1 %-38.4 %2026Q2
Geode Capital Management33.4 m1.4 bn0.1 %+0.5 %2026Q2
D. E. Shaw & Co25.5 m1.1 bn0.7 %+4.7 %2026Q2
JPMorgan Chase23.9 m1.0 bn0.1 %-28.3 %2026Q2

Latest insider transactions

DatePersonSideAmount
25/08/2026Morano Susan Epurchase100,408 USD
05/08/2026Habiger David Cpurchase99,937 USD
04/08/2026Habiger David Cpurchase6,802 USD
03/08/2026Habiger David Cpurchase50,084 USD
03/08/2026Mahoney Michael Fpurchase9.0 m USD
31/07/2026Ludwig Edward Jpurchase227,400 USD

Elected officials' disclosures

DateOfficialSideAmount
11/09/2026Ro Khannasale$1,001 - $15,000
04/09/2026Ro Khannasale$1,001 - $15,000
09/09/2026Kevin Hernsale$50,001 - $100,000
04/09/2026Kevin Hernsale$50,001 - $100,000
03/09/2026Kevin Hernsale$1,001 - $15,000

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 08/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
NYSE
IPO: 19/05/1992
ISIN code
US1011371077
Workforce
53,000
full-time employees
Chief executive
Michael F. Mahoney
Next earnings
03/02/2027

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Boston Scientific Corporation

What is the Boston Scientific Corporation share price?

Latest recorded price: 42.75 USD on 06/11/2026, for a market cap of 62.0 bn USD.

What is the revenue of Boston Scientific Corporation?

20.1 bn USD for fiscal year 2025, with net income of 2.9 bn USD (net margin 14.4 %).

When does Boston Scientific Corporation report its next earnings?

The next release is expected on 03/02/2027. EPS expected by analysts: 0.79.

What do analysts say about Boston Scientific Corporation?

Out of 44 analysts: 34 buy or strong buy, 10 hold, 0 sell or strong sell. Average price target: 54.65 USD, i.e. +30.2 % from the share price.

What is the P/E ratio of Boston Scientific Corporation?

Trailing 12-month P/E of 13.8, against 26.8 for the sector median on the same exchange (10-year median: 22.3).

Is Boston Scientific Corporation stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US1011371077).

How many employees does Boston Scientific Corporation have?

53,000 full-time employees according to the latest published profile.

Who runs Boston Scientific Corporation?

Michael F. Mahoney is the company's chief executive.

Which large funds own Boston Scientific Corporation?

As of 2026Q2, among the large funds tracked: Vanguard Group, State Street, BlackRock, Primecap Management, Fidelity.

07

Similar stocks